Autolus Therapeutics Current Ratio 2018-2021 | AUTL

Autolus Therapeutics current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Autolus Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.27B $0.03B 9.56
2021-03-31 $0.29B $0.03B 9.41
2020-12-31 $0.20B $0.03B 5.86
2020-09-30 $0.23B $0.03B 7.43
2020-06-30 $0.25B $0.03B 9.12
2020-03-31 $0.28B $0.03B 10.78
2019-12-31 $0.25B $0.03B 9.98
2019-09-30 $0.26B $0.02B 12.65
2019-06-30 $0.29B $0.02B 13.12
2019-03-31 $0.21B $0.02B 10.67
2018-12-31 $0.23B $0.02B 11.05
2018-09-30 $0.26B $0.02B 15.14
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-09-30 $0.14B $0.01B 28.33
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.408B $0.002B
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86